According to the latest report by IMARC Group, titled “Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2023-2028,” the global syphilis testing market size reached US$ 1.15 Billion in 2022. Syphilis testing refers to various laboratory tests used to diagnose sexually transmitted infection (STI) caused by the bacterium Treponema pallidum, which can have severe long-term health consequences. Early diagnosis and treatment of syphilis are crucial since, if left untreated, it may damage the nerves, blood vessels, brain, heart, joints, and other organs. Syphilis testing typically involves rapid plasma reagin (RPR), the venereal disease research laboratory (VDRL), or the treponemal antibody (TTA) tests, which can detect antibodies produced by the body in response to the presence of the bacterium. These approaches provide early detection for better treatment and alleviate the spread and development of sexually transmitted diseases (STDs).
Global Syphilis Testing Market Trends:
The increasing prevalence of STDs, including syphilis, represents one of the key factors driving the syphilis testing market growth. In line with this, the introduction of various awareness programs and campaigns by numerous governments and non-governmental organizations (NGOs) across the globe to educate the public regarding the prevention of STDs and the available treatment options is creating a positive outlook for the market. Moreover, the advent of convenient syphilis testing kits, such as rapid test strips that are widely available at online retail stores and in-store pharmacies at affordable price points and can facilitate at-home testing, further allowing for timely decision-making, is presenting remunerative growth opportunities for the market. In addition to this, an enhanced focus on early diagnosis and prevention of syphilis, the widespread implementation of effective screening programs, and the presence of favorable medical reimbursement policies are aiding in market expansion. Furthermore, significant advancements in the healthcare sector and extensive research and development (R&D) activities focused on introducing effective treatment alternatives are contributing to the market growth. Looking forward, the market value is projected to reach US$ 1.63 Billion by 2028, expanding at a CAGR of 5.8% during 2023-2028.
- Based on the type, the market is bifurcated into primary and secondary, and latent and tertiary syphilis. Between these, primary and secondary syphilis represent the largest market segment.
- On the basis of the location of testing, the market has been divided into laboratory and point-of-care (POC) testing. Amongst these, laboratory testing dominates the market, holding the largest share.
- Based on the region, the market is led by North America (the United States and Canada), followed by Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, DRG International Inc. (BioCheck Inc.), F. Hoffmann-La Roche AG, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific Inc., etc.
|Base Year of the Analysis
||Primary and Secondary Syphilis, Latent and Tertiary Syphilis
|Location of Testings Covered
||Laboratory Testing, Point-of-Care (POC) Testing
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, DRG International Inc. (BioCheck Inc.), F. Hoffmann-La Roche AG, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific Inc., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800